Fortrea Holdings Inc: Fortrea Reports Second Quarter 2026 Results
Fortrea (Nasdaq: FTRE) reported Q2 2026 revenue of $678.2 million, down from $710.3 million a year earlier. GAAP net loss was $13.2 million, while adjusted net income was $22.7 million and adjusted EBITDA $58.7 million. Book-to-bill was 1.06x and backlog $7.8 billion. Full-year guidance was raised to $2.62B-$2.69B revenue and $205M-$220M adjusted EBITDA.
How this was made
The 30-second read
Why it matters
The key tradable items are the raised full-year revenue and adjusted EBITDA ranges, alongside Q2 book-to-bill (1.06x) and backlog ($7.8B), which together can shift forward valuation assumptions for CRO demand and profitability.
Market read
A guidance increase with supportive demand indicators (book-to-bill above 1.0x) is likely to drive estimate revisions and near-term sentiment for FTRE.
What to watch
Book-to-bill and backlog are supportive, but traders may focus on whether backlog converts to revenue and whether adjusted EBITDA margin expansion is sustainable given revenue softness.
Background
Fortrea is a global contract research organization (CRO) providing clinical development services; this release covers Q2 2026 results and updates full-year 2026 guidance.
Ticker impact
Fortrea reported Q2 2026 revenue of $678.2M and raised full-year 2026 guidance to $2,620M-$2,690M revenue and $205M-$220M adjusted EBITDA.
Near-term upside bias as traders reprice 2026 revenue and adjusted EBITDA expectations; magnitude depends on how results compare to Street consensus.
The article discloses a fresh guidance raise and current-quarter operating metrics (book-to-bill, backlog) that directly affect forward estimates, though it provides no explicit consensus comparison or stock reaction.
Market effects
CRO peers may see read-across on demand durability and margin trajectory if Fortrea’s book-to-bill and EBITDA guidance are viewed as sector-representative.
Limited direct regional impact; Fortrea’s update is global but primarily affects US-listed CRO sentiment.
Moderate, as CRO spending is tied to global pharma/biotech clinical activity; guidance changes can influence broader healthcare services risk appetite.
Counterpoint
GAAP results remain loss-making and the quarter still shows revenue decline versus prior year, so the guidance raise may reflect normalization rather than a durable acceleration.
Key entities
- companyFortrea Holdings Inc
Nasdaq-listed CRO reporting Q2 2026 results and increasing full-year 2026 guidance.
